We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genome Sequencing Enables Discovery of Mutation Leading to Prader-Willi Syndrome, with Link to Autism

By LabMedica International staff writers
Posted on 09 Oct 2013
Highly accurate whole genome sequencing technology has played a pivotal role in identifying a mutation involved in causing Prader-Willi Syndrome, helping to resolve a diagnostic conundrum.

Prader-Willi Syndrome (PWS) is a rare (around 1:15,000) genetic disorder that leads to poor muscle tone, low levels of sex hormones, and a constant feeling of hunger often leading to obesity. More...
It occurs in males and females equally, and affects all races. The whole genome sequencing technology of Complete Genomics, Inc. (Mountain View, CA, USA), subsidiary of BGI-Shenzhen, was used in the identification of a point mutation causing PWS, a discovery that helped resolve a diagnostic conundrum for four young male patients who tested PWS-negative as infants.

The study, published September 29, 2013, in the journal Nature Genetics, is a collaborative effort of researchers at Baylor College of Medicine (BCM; Houston, TX, USA), the Jan and Dan Duncan Neurological Research Institute (Duncan NRI; Houston, TX, USA), and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (Houston, TX, USA).

The first patient tested PWS negative by age one year, but over the next 12 years began to manifest some of the typical PWS symptoms. Complete Genomics’ sequencing service was used in an analysis determining the genetic basis of his symptoms: a single mutation, a base deletion, was identified in the protein-coding MAGEL2 gene, in a section of chromosome 15 previously linked to PWS, and in a difficult to sequence GC rich region. It proved to be a frame-shift deletion, truncating mutation, which disrupts the MAGEL2 protein product. As MAGEL2 is only known to be expressed from the paternal gene allele (the maternal allele being silenced), it was also important to determine whether the mutation was on the maternal or paternal version of chromosome 15. In this case, the MAGEL2 mutation was confirmed to be on the paternal allele using a modified version of Complete Genomics’ Long Fragment Read technology.

To further investigate MAGEL2’s role in PLW, the researchers reviewed over 1,200 exome sequencing reports, searching for other patients with loss-of-function mutations in that gene. Three additional patients were identified – one with classic PWS, the other two with PWS-like symptoms. However, all had negative PWS tests as infants. All four patients were also diagnosed with autism spectrum disorder (ASD) and intellectual disability. These findings suggest that MAGEL2 is a new gene causing complex ASD and that MAGEL2 loss of function can contribute to several aspects of the PWS phenotype.

“This is the first study to show that point mutations can cause Prader-Willi Syndrome,” said Dr. Schaaf, assistant professor of molecular and human genetics at BCM and faculty member at the Duncan NRI; “This is an important development that increases our understanding of this complex disorder, and also gives four boys a diagnosis, which they and their parents have sought for many years.” “It also underscores the importance of being able to distinguish between maternal and paternal variants because only patients who had point mutations on the paternal copy of the MAGEL2 gene would experience the disorder,” added Dr. Brock Peters, director of research at Complete Genomics.

Related Links:

Complete Genomics
Baylor College of Medicine
The Jan and Dan Duncan Neurological Research Institute (of Texas Children's Hospital)



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.